Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Inflammation and the immune system

Topic: Brain proteins, microglia and lab models

Plain-language summary

Nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout the central nervous system, being expressed in neurons and non-neuronal cells, where they participate in a variety of physiological responses like memory, learning, locomotion, attention, among others. We will focus on the α7 nAChR subtype, which has been implicated in neuroprotection, synaptic plasticity and neuronal survival, and is considered as a potential therapeutic target for several neurological diseases. Oxidative stress and neuroinflammation are currently considered as two of the most important pathological mechanisms common in neurodegenerative diseases such as Alzheimer, Parkinson or Huntington diseases.

What this study adds

Evidence grade: Low

This is a narrative review. This review discusses the alpha7 nAChR subtype as a possible therapeutic target because of its role in neuroprotection and because oxidative stress and neuroinflammation are common in neurodegenerative diseases. It presents no tested treatment or cure for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Egea, J., Buendia, I., Parada, E., Navarro, E., León, R., & Lopez, M. G. (2015). Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2015.07.032

Vancouver

Egea J, Buendia I, Parada E, Navarro E, León R, Lopez MG. Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochemical pharmacology. 2015. doi:10.1016/j.bcp.2015.07.032. PMID: 26232730.

BibTeX

@article{egea2015-26232730,
  author  = {Egea, J. and Buendia, I. and Parada, E. and Navarro, E. and León, R. and Lopez, M. G.},
  title   = {{Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection}},
  journal = {Biochemical pharmacology},
  year    = {2015},
  doi     = {10.1016/j.bcp.2015.07.032},
  pmid    = {26232730},
  url     = {https://doi.org/10.1016/j.bcp.2015.07.032}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses the alpha7 nAChR subtype as a possible therapeutic target because of its role in neuroprotection and because oxidative stress and neuroinflammation are common in neurodegenerative diseases. It presents no tested treatment or cure for Alzheimer's disease.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Biochemical pharmacology)
Journal's citation record 3 / 4 Biochemical Pharmacology: journal h-index 292 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 298 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 22.9 citations a year over 13 year(s) since 2015
Impact for its field and year 4 / 6 Cited 10.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 3 / 4 Cited 67 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Manuela G. López: h-index 62 (OpenAlex, whole career)
Institution's track record 1 / 3 Universidad Autónoma de Madrid: institution h-index 709 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 26232730)
Free to read 0 / 2 Behind a paywall — scores zero
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Inflammation and the immune system from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →